Integration of apolipoprotein B into the SCORE2 framework: implications for cardiovascular risk prediction

被引:0
|
作者
Wong, Wen Kai [1 ,2 ,3 ]
Takeuchi, Fumihiko [1 ,4 ,5 ]
Thao, Le Thi Phuong [6 ]
Nicholls, Stephen J. [7 ,8 ]
Chew, Derek P. [7 ,8 ]
Peter, Karlheinz [1 ,2 ]
机构
[1] Univ Melbourne, Fac Med Dent & Hlth Sci, Grattan St, Parkville, Vic 3010, Australia
[2] Baker Heart & Diabet Inst, Atherothrombosis & Vasc Biol Lab, 75 Commercial Rd, Melbourne, Vic 3004, Australia
[3] Imperial Coll London, Fac Med, London, England
[4] Baker Heart & Diabet Inst, Syst Genom Lab, Melbourne, Australia
[5] Baker Heart & Diabet Inst, Cambridge Baker Syst Genom Initiat, Melbourne, Australia
[6] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Australia
[7] Monash Univ, Victorian Heart Inst, Melbourne, Australia
[8] Monash Hlth, Victorian Heart Hosp, Melbourne, Australia
基金
英国医学研究理事会;
关键词
Apolipoprotein B (ApoB); Systematic Coronary Risk Evaluation 2 (SCORE2); Cardiovascular risk prediction; UK Biobank; CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; LDL-CHOLESTEROL; I RATIO; A-I; PREVENTION; GUIDELINES; MANAGEMENT; SOCIETY; MARKERS;
D O I
10.1093/eurjpc/zwaf039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To evaluate whether integrating Apolipoprotein B (ApoB) into the Systematic Coronary Risk Evaluation 2 (SCORE2) cardiovascular risk prediction framework improves its predictive accuracy and clinical applicability within the UK Biobank population. Methods and results A 10-year prospective cohort study was conducted with 448 303 UK Biobank participants eligible for SCORE2 calculation. Three approaches were employed: (i) threshold analysis to determine the optimal ApoB cutoff for cardiovascular disease (CVD) risk prediction using Youden's Index, (ii) assessment of the synergistic effect of SCORE2 and ApoB through concordant and discordant classifications, and (iii) recalibration of the SCORE2 model by incorporating ApoB as an additional predictor. Each 0.2 g/L increase in ApoB was associated with an increased subdistribution hazard for CVD events [subdistribution hazard ratio (SHR): 1.13; 95% CI: 1.11-1.14, P < 0.001], accounting for non-cardiovascular death as a competing risk. Threshold analysis identified an optimal ApoB cutoff at 1.18 g/L; however, it demonstrated limited discriminatory performance (area under the curve 0.54), with low sensitivity (32.4%), and moderate specificity (74.4%). Individuals with both low ApoB (<1.18 g/L) and low SCORE2 risk (<5%) had a lower CVD incidence rate (232.51 per 100 000 person-years) compared with those identified as low risk by SCORE2 alone (253.69 per 100 000 person-years). Integration of ApoB into the SCORE2 model did not significantly improve the model discrimination, calibration, and net reclassification improvement. Conclusion Apolipoprotein B exhibited a dose-response relationship with cardiovascular risk but had limited standalone predictive utility within the UK Biobank population. However, combining ApoB with SCORE2 thresholds improved the identification of low-risk individuals, suggesting a complementary role for ApoB in refining cardiovascular risk stratification.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Is the cardiovascular risk SCORE2 globally valid and useful?
    Abreu, Ana
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2024, 43 (08) : 445 - 447
  • [2] Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP
    Matsushita, K.
    Kaptoge, S.
    Hageman, S. H. J.
    Visseren, F. L. J.
    Pennells, L.
    Coresh, J.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2256 - 2256
  • [3] Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP
    Matsushita, Kunihiro
    Kaptoge, Stephen
    Hageman, Steven H. J.
    Sang, Yingying
    Ballew, Shoshana H.
    Grams, Morgan E.
    Surapaneni, Aditya
    Sun, Luanluan
    Arnlov, Johan
    Bozic, Milica
    Brenner, Hermann
    Brunskill, Nigel J.
    Chang, Alex R.
    Chinnadurai, Rajkumar
    Cirillo, Massimo
    Correa, Adolfo
    Ebert, Natalie
    Eckardt, Kai Uwe
    Gansevoort, Ron T.
    Gutierrez, Orlando
    Hadaegh, Farzad
    He, Jiang
    Hwang, Shih Jen
    Jafar, Tazeen H.
    Jassal, Simerjot K.
    Kayama, Takamasa
    Kovesdy, Csaba P.
    Landman, Gijs W.
    Levey, Andrew S.
    Lloyd-Jones, Donald M.
    Major, Rupert W.
    Miura, Katsuyuki
    Muntner, Paul
    Nadkarni, Girish N.
    Nowak, Christoph
    Ohkubo, Takayoshi
    Pena, Michelle J.
    Polkinghorne, Kevan R.
    Sairenchi, Toshimi
    Schaeffner, Elke
    Schneider, Markus P.
    Shalev, Varda
    Shlipak, Michael G.
    Solbu, Marit D.
    Stempniewicz, Nikita
    Tollitt, James
    Valdivielso, Jose M.
    van der Leeuw, Joep
    Wang, Angela Yee Moon
    Wen, Chi Pang
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 30 (01) : 8 - 16
  • [4] Incremental utility of circulating biomarkers for cardiovascular risk prediction beyond the updated SCORE2 model
    Lehmacher, J.
    Toprak, B.
    Gossling, A.
    Iacoviello, L.
    Thorand, B.
    Linneberg, A.
    Kuulasmaa, K.
    Ferrario, M. M.
    Soederberg, S.
    Palmieri, L.
    Koenig, W.
    Tunstall-Pedoe, H.
    Zeller, T.
    Blankenberg, S.
    Twerenbold, R.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2262 - 2262
  • [5] Differences of cardiovascular risk assessment in clinical practice using SCORE and SCORE2
    Csenteri, Orsolya
    Jancso, Zoltan
    Szollosi, Gergo Jozsef
    Andreka, Peter
    Vajer, Peter
    OPEN HEART, 2022, 9 (02):
  • [6] Prognostic role of adding a genetic risk score to the new European SCORE2 in a cardiovascular events prediction, in a moderate-risk region
    Temtem, M.
    Palma Dos Reis, R.
    Serrao, M.
    Sa, D.
    Santos, M.
    Soares, C.
    Sousa, A. G.
    Rodrigues, M.
    Freitas, S.
    Henriques, E.
    Borges, S.
    Guerra, G.
    Ornelas, I.
    Drumond, A.
    Mendonca, M. I.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2273 - 2273
  • [7] SCORE2 Assessment in the Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis
    Ferraz-Amaro, Ivan
    Corrales, Alfonso
    Atienza-Mateo, Belen
    Vegas-Revenga, Nuria
    Prieto-Pena, Diana
    Sanchez-Martin, Julio
    Almeida, Cristina
    Quevedo-Abeledo, Juan Carlos
    Blanco, Ricardo
    Gonzalez-Gay, Miguel A.
    DIAGNOSTICS, 2021, 11 (12)
  • [8] SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
    Hageman, Steven
    Pennells, Lisa
    Ojeda, Francisco
    Kaptoge, Stephen
    Kuulasmaa, Kari
    de Vries, Tamar
    Xu, Zhe
    Kee, Frank
    Chung, Ryan
    Wood, Angela
    McEvoy, John William
    Veronesi, Giovanni
    Bolton, Thomas
    Dendale, Paul
    Ference, Brian A.
    Halle, Martin
    Timmis, Adam
    Vardas, Panos
    Danesh, John
    Graham, Ian
    Salomaa, Veikko
    Visseren, Frank
    De Bacquer, Dirk
    Blankenberg, Stefan
    Dorresteijn, Jannick
    Di Angelantonio, Emanuele
    Achenbach, Stephan
    Aleksandrova, Krasimira
    Amiano, Pilar
    Amouyel, Philippe
    Andersson, Jonas
    Bakker, Stephan J. L.
    Costa, Rui Bebiano Da Providencia
    Beulens, Joline W. J.
    Blaha, Michael
    Bobak, Martin
    Boer, Jolanda M. A.
    Bonet, Catalina
    Bonnet, Fabrice
    Boutron-Ruault, Marie-Christine
    Braaten, Tonje
    Brenner, Hermann
    Brunner, Fabian
    Brunner, Eric J.
    Brunstrom, Mattias
    Buring, Julie
    Butterworth, Adam S.
    Capkova, Nadezda
    Cesana, Giancarlo
    Chrysohoou, Christina
    EUROPEAN HEART JOURNAL, 2021, 42 (25) : 2439 - 2454
  • [9] The importance and usefulness of SCORE2 in cardiovascular prevention
    Cotrim, Luis
    Rabacal, Carlos
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2024, 43 (11) : 611 - 612
  • [10] Cardiovascular risk assessment with SCORE, SCORE2 and D:A:D in people living with HIV with high prevalence of cardiovascular risk factors
    Miguel, M. J.
    Cruz, D.
    Albuquerque, A. A.
    Gomes, A.
    Pintassilgo, I.
    Marques, N.
    HIV MEDICINE, 2023, 24 : 283 - 283